Page 124 - Read Online

Liu et al. Necroptosis and immune dysfunction in ALS

damage-associated molecular patterns and its physiological relevance. 59. Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 Cells.
Immunity 2013;38:209-23. Annu Rev Immunol 2009;27:485-517.
47. Gowing G, Dequen F, Soucy G, Julien JP. Absence of tumor 60. Maddur MS, Miossec P, Kaveri SV, Bayry J. Th17 cells: biology,
necrosis factor-alpha does not affect motor neuron disease caused by pathogenesis of autoimmune and inflammatory diseases, and
superoxide dismutase 1 mutations. J Neurosci 2006;26:11397-402. therapeutic strategies. Am J Pathol 2012;181:8-18.
48. Kriz J, Nguyen MD, Julien JP. Minocycline slows disease progression 61. Rentzos M, Rombos A, Nikolaou C, Zoga M, Zouvelou V,
in a mouse model of amyotrophic lateral sclerosis. Neurobiol Dis Dimitrakopoulos A, Alexakis T, Tsoutsou A, Samakovli A,
2002;10:268-78. Michalopoulou M, Evdokimidis J. Interleukin-17 and interleukin-23
49. Gordon PH, Moore DH, Miller RG, Florence JM, Verheijde JL, are elevated in serum and cerebrospinal fluid of patients with
Doorish C, Hilton JF, Spitalny GM, MacArthur RB, Mitsumoto H, ALS: a reflection of Th17 cells activation? Acta Neurol Scand
Neville HE, Boylan K, Mozaffar T, Belsh JM, Ravits J, Bedlack RS, 2010;122:425-9.
Graves MC, McCluskey LF, Barohn RJ, Tandan R; Western ALS Study 62. Fiala M, Chattopadhay M, La Cava A, Tse E, Liu G, Lourenco E, Eskin
Group. Efficacy of minocycline in patients with amyotrophic lateral A, Liu PT, Magpantay L, Tse S, Mahanian M, Weitzman R, Tong J,
sclerosis: a phase III randomised trial. Lancet Neurol 2007;6:1045-53. Nguyen C, Cho T, Koo P, Sayre J, Martinez-Maza O, Rosenthal MJ,
50. Kiaei M, Kipiani K, Petri S, Choi DK, Chen J, Calingasan NY, Beal Wiedau-Pazos M. IL-17A is increased in the serum and in spinal cord
MF. Integrative role of cPLA with COX-2 and the effect of non- CD8 and mast cells of ALS patients. J Neuroinflammation 2010;7:76.
steriodal anti-inflammatory drugs in a transgenic mouse model of 63. Moreau C, Devos D, Brunaud-Danel V, Defebvre L, Perez T, Destée
amyotrophic lateral sclerosis. J Neurochem 2005;93:403-11. A, Tonnel AB, Lassalle P, Just N. Elevated IL-6 and TNF-alpha
51. Brown RH Jr, Hauser SL, Harrington H, Weiner HL. Failure of levels in patients with ALS: inflammation or hypoxia? Neurology
immunosuppression with a ten- to 14-day course of high-dose 2005;65:1958-60.
intravenous cyclophosphamide to alter the progression of amyotrophic 64. Xin J, Wainwright DA, Serpe CJ, Sanders VM, Jones KJ. Phenotype
lateral sclerosis. Arch Neurol 1986;43:383-4. of CD4+ T cell subsets that develop following mouse facial nerve
52. Drachman DB, Chaudhry V, Cornblath D, Kuncl RW, Pestronk axotomy. Brain Behav Immun 2008;22:528-37.
A, Clawson L, Mellits ED, Quaskey S, Quinn T, Calkins A. Trial 65. Horner RD, Kamins KG, Feussner JR, Grambow SC, Hoff-Lindquist
of immunosuppression in amyotrophic lateral sclerosis using total J, Harati Y, Mitsumoto H, Pascuzzi R, Spencer PS, Tim R, Howard
lymphoid irradiation. Ann Neurol 1994;35:142-50.
53. Banerjee R, Mosley RL, Reynolds AD, Dhar A, Jackson-Lewis D, Smith TC, Ryan MA, Coffman CJ, Kasarskis EJ. Occurrence of
V, Gordon PH, Przedborski S, Gendelman HE. Adaptive immune amyotrophic lateral sclerosis among Gulf War veterans. Neurology
neuroprotection in G93A-SOD1 amyotrophic lateral sclerosis mice. 2003;61:742-9.
PLoS One 2008;3:e2740. 66. Scarmeas N, Shih T, Stern Y, Ottman R, Rowland LP. Premorbid
54. Chiu IM, Chen A, Zheng Y, Kosaras B, Tsiftsoglou SA, Vartanian weight, body mass, and varsity athletics in ALS. Neurology
TK, Brown RH Jr, Carroll MC. T lymphocytes potentiate endogenous 2002;59:773-5.
neuroprotective inflammation in a mouse model of ALS. Proc Natl 67. Chiò A, Benzi G, Dossena M, Mutani R, Mora G. Severely increased
Acad Sci U S A 2008;105:17913-8. risk of amyotrophic lateral sclerosis among Italian professional
55. Deboy CA, Xin J, Byram SC, Serpe CJ, Sanders VM, Jones KJ. football players. Brain 2005;128:472-6.
Immune-mediated neuroprotection of axotomized mouse facial 68. Ni A, Yang T, Mesnard-Hoaglin NA, Gutierrez R, Stubbs EB Jr,
motoneurons is dependent on the IL-4/STAT6 signaling pathway in McGuire SO, Sanders VM, Jones KJ, Foecking EM, Xin J. Th17
CD4(+) T cells. Exp Neurol 2006;201:212-24. cell response in SOD1G93A mice following motor nerve injury.
56. Henkel JS, Beers DR, Wen S, Rivera AL, Toennis KM, Appel JE, Mediators Inflamm 2016;2016:6131234.
Zhao W, Moore DH, Powell SZ, Appel SH. Regulatory T-lymphocytes 69. Moran LB, Graeber MB. The facial nerve axotomy model. Brain Res
mediate amyotrophic lateral sclerosis progression and survival. Brain Res Rev 2004;44:154-78.
EMBO Mol Med 2013;5:64-79. 70. Frey D, Schneider C, Xu L, Borg J, Spooren W, Caroni P. Early and
57. Zhao W, Beers DR, Liao B, Henkel JS, Appel SH. Regulatory T selective loss of neuromuscular synapse subtypes with low sprouting
lymphocytes from ALS mice suppress microglia and effector T competence in motoneuron diseases. J Neurosci 2000;20:2534-42.
lymphocytes through different cytokine-mediated mechanisms. 71. Fischer LR, Culver DG, Tennant P, Davis AA, Wang M, Castellano-
Neurobiol Dis 2012;48:418-28. Sanchez A, Khan J, Polak MA, Glass JD. Amyotrophic lateral
58. Mesnard-Hoaglin NA, Xin J, Haulcomb MM, Batka RJ, Sanders VM, sclerosis is a distal axonopathy: evidence in mice and man. Exp
Jones KJ. SOD1(G93A) transgenic mouse CD4(+) T cells mediate Neurol 2004;185:232-40.
neuroprotection after facial nerve axotomy when removed from 72. Xin J, Wainwright DA, Mesnard NA, Serpe CJ, Sanders VM, Jones
a suppressive peripheral microenvironment. Brain Behav Immun KJ. IL-10 within the CNS is necessary for CD4+ T cells to mediate
2014;40:55-60. neuroprotection. Brain Behav Immun 2011;25:820-9.

116 Neuroimmunology and Neuroinflammation ¦ Volume 4 ¦ June 16, 2017